These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 24249647

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Complement therapy in atypical haemolytic uraemic syndrome (aHUS).
    Wong EK, Goodship TH, Kavanagh D.
    Mol Immunol; 2013 Dec 15; 56(3):199-212. PubMed ID: 23810412
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome.
    Syed YY.
    Drugs; 2021 Apr 15; 81(5):587-594. PubMed ID: 33738756
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next?
    Fakhouri F, Frémeaux-Bacchi V.
    Nat Rev Nephrol; 2013 Sep 15; 9(9):495-6. PubMed ID: 23917793
    [No Abstract] [Full Text] [Related]

  • 48. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab.
    Gäckler A, Kaulfuß M, Rohn H, Vogel U, Claus H, Feldkamp T, Kribben A, Witzke O.
    Nephrol Dial Transplant; 2020 Feb 01; 35(2):298-303. PubMed ID: 29992261
    [Abstract] [Full Text] [Related]

  • 49. Atypical hemolytic uremic syndrome: a new drug program and first Polish adult patient treated with eculizumab.
    Ruszkowski J, Heleniak Z, Dębska-Ślizień A.
    Pol Merkur Lekarski; 2018 Sep 21; 45(267):119-121. PubMed ID: 30240381
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions.
    Békássy ZD, Kristoffersson AC, Cronqvist M, Roumenina LT, Rybkine T, Vergoz L, Hue C, Fremeaux-Bacchi V, Karpman D.
    Nephrol Dial Transplant; 2013 Nov 21; 28(11):2899-907. PubMed ID: 24009284
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.
    van den Brand JA, Verhave JC, Adang EM, Wetzels JF.
    Nephrol Dial Transplant; 2017 Jan 01; 32(suppl_1):i115-i122. PubMed ID: 28391343
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M, Tanabe K.
    Nephrology (Carlton); 2016 Jul 01; 21 Suppl 1():9-13. PubMed ID: 26988663
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T, Okumi M, Unagami K, Kanzawa T, Sawada A, Kawanishi K, Omoto K, Ishida H, Tanabe K.
    Nephrology (Carlton); 2016 Jul 01; 21 Suppl 1():35-40. PubMed ID: 26970541
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.